Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2014 08:18 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at Stifel Healthcare Conference 2014

BURLINGTON, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CFO Frederick Driscoll will present at the Stifel Healthcare Conference 2014 on...
November 13, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Third-Quarter 2014 Financial Results

Recent Highlights Following meeting with U.S. Food & Drug Administration (FDA), announced plans to accelerate initiation of a Phase 3 clinical trial for FX006 Bolstered intellectual...
November 06, 2014 16:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Third-Quarter 2014 Financial Results

BURLINGTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the company will host a conference call and webcast to report its third-quarter 2014...
September 17, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

- Company to host conference call tomorrow, September 18, 2014 at 9:00 a.m. ET to discuss the clinical hold BURLINGTON, Mass., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc....
September 09, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Candidate FX006

BURLINGTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (No....
September 03, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Start FX006 Phase 3 Pivotal Trial in 2014; Following FDA Meeting, Development Plan Advanced by One Year

- Company to Host Conference Call Tomorrow, September 4, 2014 at 8:30 a.m. EST, During Which Management Will Discuss Updated Timing and Plans BURLINGTON, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) --...
August 07, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Second-Quarter 2014 Financial Results

Recent Highlights Announced positive topline results from Phase 2a synovial fluid pharmacokinetic (PK) study of lead clinical candidate FX006 Initiated confirmatory Phase 2b clinical trial...
July 31, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014

BURLINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the company will host a conference call and webcast to report its second quarter 2014...
July 28, 2014 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics and Southwest Research Institute(R) (SwRI(R)) Sign Worldwide Exclusive License for Proprietary Microsphere Manufacturing Technologies

Flexion secures expanded intellectual property for manufacturing of FX006 sustained- release microsphere drug candidate License includes musculoskeletal disorders and several...
July 24, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Board Changes

- Sandesh (Sandy) Mahatme of Sarepta Therapeutics Appointed New Board Member - Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Dr. Rafaéle...